Motol University Hospital
Prague 5 150 06
4 studies enrolling now · 13 studies all time
What they study most
Breast Cancer, Cortical Dysplasia, Cystic Fibrosis, Focal Epilepsy, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, HER2 Positive Breast Cancer, Low-grade Glioma, Muscular Diseases, Muscular Disorders, Atrophic, Muscular Dystrophies, Muscular Dystrophy, Duchenne
Studies at this site
- A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections — Recruiting now
- A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer — Recruiting now
- A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) — Recruiting now
- An Open-label Study of XEN1101 in Epilepsy — Enrolling by invitation
- A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy — Running, not enrolling
- DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) — Running, not enrolling
- Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease — Starting soon
- Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis — Completed
- An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy — Stopped early
- Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) — Completed
- Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients — Completed
- Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy — Stopped early
- MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients — Stopped early